Emblation
- Company typePrivate
- Founded2008
- HeadquartersAlloa, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Emblation firmographics
Firmographics- Name
- Emblation
- Website
- https://emblation.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Where Emblation is headquartered
LocationHeadquarters
- HQ city
- Alloa
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Emblation business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Emblation product offering
Product offeringCore offering
Emblation is a medical technology company that develops medical research products and immune-modulating treatments. Founded in 2008 and headquartered in Alloa, United Kingdom, the company operates in the medical devices and therapeutics space, focusing on immune-system-based therapeutic interventions.
Differentiator
Problem solved
Functional benefit
Products and services
- Immune-Modulating Treatments
- Medical Research Products
Companies that use Emblation
Customer profileIdeal customer profiles1 record
Emblation technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Emblation partnerships and signals
Strategic signalRecent moves1 record
Expansion highlights1 record
Emblation competitors and assessment
Company assessmentBroad incumbents
- Cynosure: Cynosure manufactures energy-based aesthetic and medical devices (laser, RF, light-based). It is comparable to Emblation as a commercial-scale player in the same electromagnetic/energy-based device category that Emblation occupies with its immune-modulating platform.
- Cutera: Cutera develops laser and energy-based devices for dermatology and aesthetics. It competes in the same energy-based device space that Emblation addresses, with overlapping clinician customers (dermatologists, podiatrists, plastic surgeons) and similar capital-equipment sales motion.
- InMode: InMode manufactures radiofrequency and electromagnetic medical/aesthetic devices. It is a direct competitor to Emblation in the energy-based medical device category, selling capital equipment to similar clinical specialties.
- Alma Lasers: Alma Lasers manufactures a broad portfolio of laser, RF, ultrasound, and energy-based medical/aesthetic devices. It overlaps with Emblation's energy-based device category and shares similar clinical end markets (dermatology, aesthetics, podiatry).
- Solta Medical (Bausch Health): Solta Medical makes energy-based devices for skin treatments (Thermage RF, Fraxel laser, Clear+Brilliant). It serves the same clinical specialties as Emblation and competes in the same energy-based dermatology/podiatry device market.
- Syneron-Candela: Syneron-Candela develops and markets medical aesthetic and dermatology devices based on laser, RF, and other energy modalities. It is comparable to Emblation as a larger incumbent operating in the same energy-based clinical device space.
- BTG (Boston Scientific): BTG, now part of Boston Scientific, historically developed interventional and specialty medical devices including energy-based platforms. It is a broad incumbent comparable to Emblation as a scaled medical device acquirer/operator with adjacent therapeutic energy-delivery platforms.
Direct peers
- Miramar Labs (miraDry): Miramar Labs markets miraDry, a microwave-based device for treating hyperhidrosis using controlled electromagnetic energy. It is the closest direct peer to Emblation's Swift platform — same core technology modality (controlled microwave energy applied clinically) and same device-based immune/tissue modulation model.
Emerging players
- EDAP TMS: EDAP TMS develops therapeutic ultrasound devices (HIFU) for urology and other clinical indications. It is an emerging player comparable to Emblation in that both use controlled energy delivery for clinical tissue/immune effects and pursue indication-broadening strategies.
- HistoSonics: HistoSonics is developing focused ultrasound-based tissue destruction devices. It is comparable to Emblation as an emerging player in energy-based clinical devices with a platform-technology approach targeting multiple indications.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Emblation social profiles
Digital presenceEmblation financial estimates
Financial estimateRevenue estimate
Valuation estimate
Emblation leadership team
Management profileNumber of profiles
Emblation funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Emblation M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Emblation
What does Emblation do?
Emblation is a medical technology company that develops medical research products and immune-modulating treatments. Founded in 2008 and headquartered in Alloa, United Kingdom, the company operates in the medical devices and therapeutics space, focusing on immune-system-based therapeutic interventions.
When was Emblation founded?
Emblation was founded in 2008. It employs 11 to 50 people.
Where is Emblation based?
Emblation is headquartered in Alloa, United Kingdom, in the Europe region.
Who are Emblation's main competitors?
Broad incumbents on record are Cynosure, Cutera, InMode, Alma Lasers, Solta Medical (Bausch Health), Syneron-Candela and BTG (Boston Scientific). Miramar Labs (miraDry) is listed as a direct peer. Emerging players are EDAP TMS and HistoSonics.
Does Emblation have an API?
No public API is recorded for Emblation.